Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements

Anesthesia and Analgesia

Volumn 111, Issue 4, 2010, Pages 849-855

  Garvin, Sean ^a   FitzGerald, Daniel C ^a   Despotis, George ^b   Shekar, Prem ^a   Body, Simon C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; ARTICLE; BIOLOGICAL MONITORING; CARDIOPULMONARY BYPASS; COMPARATIVE STUDY; DATA BASE; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; PREDICTION; PRIORITY JOURNAL; RELIABILITY; BLOOD CLOTTING TIME; HEMOSTASIS; INSTRUMENTATION; MIDDLE AGED; PREDICTION AND FORECASTING; REPRODUCIBILITY; RETROSPECTIVE STUDY; STANDARD; TREATMENT FAILURE;

AGED; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOSTATIC TECHNIQUES; HEPARIN; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; WHOLE BLOOD COAGULATION TIME;

EID: 77957720087     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181b79d09     Document Type: Article

References (28)

1. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980;79:97-102
2. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-440
3. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a doseresponse curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-689
4. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of wholeblood heparin concentration and activated clotting time. Perfusion 2003;18:269-276
5. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54
6. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45
7. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902-908
8. Bowie J, Kemma G. Automated management of heparin anticoagulation in cardiovascular surgery. Proc Am Acad Cardiovasc Perf 1985;6:1-10
9. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998;45:10-18
10. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008;22:47-52
11. Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. Ann Thorac Surg 1996;61:795-799
12. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-1082
13. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996;112:154-161
14. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956;5:328-345
15. Medtronic Perfusion Systems. Hepcon HMS Plus operator s manual. Minneapolis, MN, 2001
16. Ranucci M, Isgro G, Cazzaniga A, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002;17:199-204
17. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873
18. Broze GJ Jr, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987;69:150-155
19. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175-185
20. Adams MJ, Cardigan RA, Marchant WA, Grocott MP, Mythen MG, Mutch M, Purdy G, Mackie IJ, Machin SJ. Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2002;16:59-63
21. Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB. Regulation of thrombin generation by TFPI in plasma without and with heparin. Transl Res 2009;153:124-131
22. Hellstern P, Bach J, Simon M, Saggau W. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest- POC-Hi. J Extra Corpor Technol 2007;39:81-86
23. Hoffmann U, Harenberg J, Bauer K, Huhle G, Tolle AR, Feuring M, Christ M. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose lowmolecular- weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagul Fibrinolysis 2002;13:289-296
24. Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S, Spencer FC. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-111
25. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-684
26. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-240
27. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981;31:161-166
28. Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837-841